Compare Mesoblast Limited (MESO) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Prospect Capital Corporation — how do they compare? Mesoblast Limited trades at $16.68 (market cap $2.16B), while Prospect Capital Corporation trades at $2.27 (market cap $1.15B). The key difference: Mesoblast Limited is the larger of the two by market cap, and Prospect Capital Corporation pays a 21.83% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | PSEC | |
|---|---|---|
Market Cap | $2.16B | $1.15B |
Sector | Technology | Financials |
52-Week High | $20.96 | $3.05 |
52-Week Low | $12.88 | $2.11 |
Enterprise Value | $2.17B | — |
Dividend Yield | — | 21.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
PSEC trades at $2.33, up 5.43% in the last session, with a neutral technical signal and bearish moving averages. The company shows mixed fundamentals, with a low P/B of 0.4 and recent quarterly EPS beats, but negative revenue and net income in 2025. Recent news highlights a dividend increase for an affiliate fund and the sale of Valley Electric for a 4.8x return.
Outlook is cautious; the stock offers value with a low P/B and dividend yield, but significant risks include persistent negative profitability, high P/S ratio, and analyst skepticism. Investment appeal hinges on portfolio turnaround and sustained dividend stability amid operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
